Polyrizon Ltd.

Contributing Author

Recent Articles by Polyrizon Ltd.

Apr-08	Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements PLRZ GlobeNewswire
Apr-07	Polyrizon Ltd. Announces $3.5 Million Registered Direct Offering and Private Placement PLRZ -9.92% GlobeNewswire
Mar-26	Polyrizon Provides 2025 and Recent Highlights PLRZ GlobeNewswire
Mar-25	Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 PLRZ GlobeNewswire
Mar-24	Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications PLRZ -5.03% GlobeNewswire
Mar-17	Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program PLRZ GlobeNewswire
Mar-10	Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study PLRZ GlobeNewswire
Feb-26	Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product PLRZ GlobeNewswire
Feb-10	Polyrizon Intends to Secure Controlling Stake in Profitable Private Jet Operator PLRZ GlobeNewswire
Feb-06	Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation PLRZ GlobeNewswire
Feb-04	Polyrizon Intends to Acquire 51% Stake in Global Private Aviation Company PLRZ -15.16% GlobeNewswire
Jan-22	Polyrizon Advances Regulatory Path with Initiation of Usability Study Program for NASARIX Allergy Blocker PLRZ GlobeNewswire
Jan-13	Polyrizon to Explore Revenue-Generating Investment Opportunities in High-Growth Sectors, Leveraging Strong Cash Position and Debt-Free Balance Sheet PLRZ GlobeNewswire
Jan-08	Polyrizon Completes Branding Process for PL-14 Allergy Blocker with Brand Name NASARIX PLRZ +8.36% GlobeNewswire
Jan-05	Polyrizon Announces New Pre-Clinical Results: PL-14 Demonstrates Significant Allergen-Blocking Performance Compared to a Standard Comparator PLRZ GlobeNewswire
Jan-02	As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated PLRZ +50.18% GlobeNewswire
Dec-29	Polyrizon to Explore Revenue-Generating Real Asset Opportunities, Leveraging Strong Cash Position and Debt-Free Balance Sheet PLRZ GlobeNewswire
Dec-19	Polyrizon Submits Pre-Request for Designation to FDA for PL-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses PLRZ -6.73% GlobeNewswire
Dec-11	Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program PLRZ +11.46% GlobeNewswire
Dec-08	Polyrizon Completes FDA Pre-Submission Meeting for PL-14 Allergy Blocker Nasal Spray PLRZ -15.65% GlobeNewswire
Dec-04	From Lab to Global Impact: Polyrizon's Journey to Potentially Redefining Next-Generation Nasal Protection PLRZ +104.51% GlobeNewswire
Dec-03	Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product PLRZ GlobeNewswire
Dec-03	Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone product PLRZ GlobeNewswire
Dec-02	Polyrizon Announces Successful Completion of Key Manufacturing Upscaling Milestone for Its Nasal Spray Platform PLRZ +131.96% GlobeNewswire
Nov-06	Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation PLRZ -5.31% GlobeNewswire
Oct-06	Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy PLRZ GlobeNewswire
Sep-19	Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker PLRZ +7.69% GlobeNewswire
Sep-12	Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study PLRZ +22.76% GlobeNewswire
Aug-14	Polyrizon Regains Compliance with Nasdaq Listing Requirements PLRZ +10.89% GlobeNewswire
Jul-22	Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study PLRZ +59.73% GlobeNewswire
Jul-15	Polyrizon Retains Nasdaq Listing Following Hearings Panel PLRZ +52.47% GlobeNewswire
Jun-12	Polyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS Therapeutics PLRZ +33.75% GlobeNewswire
May-23	Polyrizon Announces Receipt of Nasdaq Delisting Notice PLRZ -24.00% PLRZ -19.05% GlobeNewswire
May-21	Polyrizon Emerges with Positive Preclinical Data on Nasal Protection Platform PLRZ GlobeNewswire
May-13	Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment PLRZ -91.86% GlobeNewswire

Polyrizon Ltd.

Recent Articles by Polyrizon Ltd.

Upgrade your Finviz experience